Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration

Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration
80%69%58%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 66.6%May 28 • YES 71.4%
Kodiak Sciences Inc ($KOD)
No stock close$37.89$35.92$33.94May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • KOD $35.02May 19 • KOD $34.42May 20 • KOD $36.22May 21 • KOD $37.41May 22 • KOD $36.23May 26 • KOD $36.00May 27 • KOD $35.09May 28 • KOD $36.12

Will this trial show a positive result on best corrected visual acuity (BCVA), Mean change in BCVA from Day 1 to Year 1, Week 48?

Paper Trading
Create account to trade
Scientific editorial illustration for Wet Age-Related Macular Degeneration

Wet Age-Related Macular Degeneration

Wet age-related macular degeneration causes leaky abnormal blood vessels to damage central vision used for reading and recognizing faces. Best corrected vision shows whether treatment helps people see better on an eye chart.